Do HIV-positive women receive depression treatment that meets best practice guidelines?

Judith A. Cook, Jane K. Burke-Miller, Dennis D. Grey, Jennifer Cocohoba, Chenlong Liu, Rebecca M. Schwartz, Elizabeth T. Golub, Kathryn Anastos, Pamela J. Steigman, Mardge H. Cohen

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

This study addressed whether psychopharmacologic and psychotherapeutic treatment of depressed HIV? women met standards defined in the best practice literature, and tested hypothesized predictors of standardconcordant care. 1,352 HIV-positive women in the multicenter Women's Interagency HIV Study were queried about depressive symptoms and mental health service utilization using standards published by the American Psychiatric Association and the Agency for Healthcare Research and Quality to define adequate depression treatment. We identified those who: (1) reported clinically significant depressive symptoms (CSDS) using Centers for Epidemiological Studies-Depression Scale scores of C16≤ or (2) had lifetime diagnoses of major depressive disorder (MDD) assessed by World Mental Health Composite International Diagnostic Interviews plus concurrent elevated depressive symptoms in the past 12 months. Adequate treatment prevalence was 46.2 % (n = 84) for MDD and 37.9 % (n = 211) for CSDS. Multivariable logistic regression analysis found that adequate treatment was more likely among women who saw the same primary care provider consistently, who had poorer self-rated role functioning, who paid out-of-pocket for healthcare, and who were not African American or Hispanic/Latina. This suggests that adequate depression treatment may be increased by promoting healthcare provider continuity, outreaching individuals with lower levels of reported role impairment, and addressing the specific needs and concerns of African American and Hispanic/Latina women.X

Original languageEnglish (US)
Pages (from-to)1094-1102
Number of pages9
JournalAIDS and Behavior
Volume18
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Practice Guidelines
HIV
Depression
Hispanic Americans
Major Depressive Disorder
African Americans
Therapeutics
Health Services Research
Mental Health Services
Health Personnel
HIV-1
Epidemiologic Studies
Primary Health Care
Mental Health
Logistic Models
Regression Analysis
Interviews
Delivery of Health Care

Keywords

  • Depression treatment
  • Psychopharmacology
  • Psychotherapy
  • Women and HIV

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases
  • Social Psychology
  • Medicine(all)

Cite this

Cook, J. A., Burke-Miller, J. K., Grey, D. D., Cocohoba, J., Liu, C., Schwartz, R. M., ... Cohen, M. H. (2014). Do HIV-positive women receive depression treatment that meets best practice guidelines? AIDS and Behavior, 18(6), 1094-1102. https://doi.org/10.1007/s10461-013-0679-6

Do HIV-positive women receive depression treatment that meets best practice guidelines? / Cook, Judith A.; Burke-Miller, Jane K.; Grey, Dennis D.; Cocohoba, Jennifer; Liu, Chenlong; Schwartz, Rebecca M.; Golub, Elizabeth T.; Anastos, Kathryn; Steigman, Pamela J.; Cohen, Mardge H.

In: AIDS and Behavior, Vol. 18, No. 6, 2014, p. 1094-1102.

Research output: Contribution to journalArticle

Cook, JA, Burke-Miller, JK, Grey, DD, Cocohoba, J, Liu, C, Schwartz, RM, Golub, ET, Anastos, K, Steigman, PJ & Cohen, MH 2014, 'Do HIV-positive women receive depression treatment that meets best practice guidelines?', AIDS and Behavior, vol. 18, no. 6, pp. 1094-1102. https://doi.org/10.1007/s10461-013-0679-6
Cook JA, Burke-Miller JK, Grey DD, Cocohoba J, Liu C, Schwartz RM et al. Do HIV-positive women receive depression treatment that meets best practice guidelines? AIDS and Behavior. 2014;18(6):1094-1102. https://doi.org/10.1007/s10461-013-0679-6
Cook, Judith A. ; Burke-Miller, Jane K. ; Grey, Dennis D. ; Cocohoba, Jennifer ; Liu, Chenlong ; Schwartz, Rebecca M. ; Golub, Elizabeth T. ; Anastos, Kathryn ; Steigman, Pamela J. ; Cohen, Mardge H. / Do HIV-positive women receive depression treatment that meets best practice guidelines?. In: AIDS and Behavior. 2014 ; Vol. 18, No. 6. pp. 1094-1102.
@article{57a57594ad7f4a03bd958e4cc302ab28,
title = "Do HIV-positive women receive depression treatment that meets best practice guidelines?",
abstract = "This study addressed whether psychopharmacologic and psychotherapeutic treatment of depressed HIV? women met standards defined in the best practice literature, and tested hypothesized predictors of standardconcordant care. 1,352 HIV-positive women in the multicenter Women's Interagency HIV Study were queried about depressive symptoms and mental health service utilization using standards published by the American Psychiatric Association and the Agency for Healthcare Research and Quality to define adequate depression treatment. We identified those who: (1) reported clinically significant depressive symptoms (CSDS) using Centers for Epidemiological Studies-Depression Scale scores of C16≤ or (2) had lifetime diagnoses of major depressive disorder (MDD) assessed by World Mental Health Composite International Diagnostic Interviews plus concurrent elevated depressive symptoms in the past 12 months. Adequate treatment prevalence was 46.2 {\%} (n = 84) for MDD and 37.9 {\%} (n = 211) for CSDS. Multivariable logistic regression analysis found that adequate treatment was more likely among women who saw the same primary care provider consistently, who had poorer self-rated role functioning, who paid out-of-pocket for healthcare, and who were not African American or Hispanic/Latina. This suggests that adequate depression treatment may be increased by promoting healthcare provider continuity, outreaching individuals with lower levels of reported role impairment, and addressing the specific needs and concerns of African American and Hispanic/Latina women.X",
keywords = "Depression treatment, Psychopharmacology, Psychotherapy, Women and HIV",
author = "Cook, {Judith A.} and Burke-Miller, {Jane K.} and Grey, {Dennis D.} and Jennifer Cocohoba and Chenlong Liu and Schwartz, {Rebecca M.} and Golub, {Elizabeth T.} and Kathryn Anastos and Steigman, {Pamela J.} and Cohen, {Mardge H.}",
year = "2014",
doi = "10.1007/s10461-013-0679-6",
language = "English (US)",
volume = "18",
pages = "1094--1102",
journal = "AIDS and Behavior",
issn = "1090-7165",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Do HIV-positive women receive depression treatment that meets best practice guidelines?

AU - Cook, Judith A.

AU - Burke-Miller, Jane K.

AU - Grey, Dennis D.

AU - Cocohoba, Jennifer

AU - Liu, Chenlong

AU - Schwartz, Rebecca M.

AU - Golub, Elizabeth T.

AU - Anastos, Kathryn

AU - Steigman, Pamela J.

AU - Cohen, Mardge H.

PY - 2014

Y1 - 2014

N2 - This study addressed whether psychopharmacologic and psychotherapeutic treatment of depressed HIV? women met standards defined in the best practice literature, and tested hypothesized predictors of standardconcordant care. 1,352 HIV-positive women in the multicenter Women's Interagency HIV Study were queried about depressive symptoms and mental health service utilization using standards published by the American Psychiatric Association and the Agency for Healthcare Research and Quality to define adequate depression treatment. We identified those who: (1) reported clinically significant depressive symptoms (CSDS) using Centers for Epidemiological Studies-Depression Scale scores of C16≤ or (2) had lifetime diagnoses of major depressive disorder (MDD) assessed by World Mental Health Composite International Diagnostic Interviews plus concurrent elevated depressive symptoms in the past 12 months. Adequate treatment prevalence was 46.2 % (n = 84) for MDD and 37.9 % (n = 211) for CSDS. Multivariable logistic regression analysis found that adequate treatment was more likely among women who saw the same primary care provider consistently, who had poorer self-rated role functioning, who paid out-of-pocket for healthcare, and who were not African American or Hispanic/Latina. This suggests that adequate depression treatment may be increased by promoting healthcare provider continuity, outreaching individuals with lower levels of reported role impairment, and addressing the specific needs and concerns of African American and Hispanic/Latina women.X

AB - This study addressed whether psychopharmacologic and psychotherapeutic treatment of depressed HIV? women met standards defined in the best practice literature, and tested hypothesized predictors of standardconcordant care. 1,352 HIV-positive women in the multicenter Women's Interagency HIV Study were queried about depressive symptoms and mental health service utilization using standards published by the American Psychiatric Association and the Agency for Healthcare Research and Quality to define adequate depression treatment. We identified those who: (1) reported clinically significant depressive symptoms (CSDS) using Centers for Epidemiological Studies-Depression Scale scores of C16≤ or (2) had lifetime diagnoses of major depressive disorder (MDD) assessed by World Mental Health Composite International Diagnostic Interviews plus concurrent elevated depressive symptoms in the past 12 months. Adequate treatment prevalence was 46.2 % (n = 84) for MDD and 37.9 % (n = 211) for CSDS. Multivariable logistic regression analysis found that adequate treatment was more likely among women who saw the same primary care provider consistently, who had poorer self-rated role functioning, who paid out-of-pocket for healthcare, and who were not African American or Hispanic/Latina. This suggests that adequate depression treatment may be increased by promoting healthcare provider continuity, outreaching individuals with lower levels of reported role impairment, and addressing the specific needs and concerns of African American and Hispanic/Latina women.X

KW - Depression treatment

KW - Psychopharmacology

KW - Psychotherapy

KW - Women and HIV

UR - http://www.scopus.com/inward/record.url?scp=84905577511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905577511&partnerID=8YFLogxK

U2 - 10.1007/s10461-013-0679-6

DO - 10.1007/s10461-013-0679-6

M3 - Article

C2 - 24402689

AN - SCOPUS:84905577511

VL - 18

SP - 1094

EP - 1102

JO - AIDS and Behavior

JF - AIDS and Behavior

SN - 1090-7165

IS - 6

ER -